Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM)

被引：11

作者：

Facchinetti, Francesco ^{[1
]}

Pilotto, Sara ^{[2
]}

Metro, Giulio ^{[3
]}

Baldini, Editta ^{[4
]}

Bertolaccini, Luca ^{[5
]}

Cappuzzo, Federico ^{[6
]}

Delmonte, Angelo ^{[7
]}

Gasparini, Stefano ^{[8
,9
]}

Inno, Alessandro ^{[10
]}

Marchetti, Antonio ^{[11
]}

Passiglia, Francesco ^{[12
]}

Puma, Francesco ^{[13
]}

Ricardi, Umberto ^{[14
]}

Rossi, Antonio ^{[15
]}

Crino, Lucio ^{[7
]}

Novellol, Silvia ^{[12
]}

机构：

[1] Univ Paris Saclay, INSERM, U981, Gustave Roussy Canc Campus, Villejuif, France

[2] Univ Verona, Verona Univ Hosp, Med Oncol, Verona, Italy

[3] Azienda Osped Perugia, Santa Maria Misericordia Hosp, Med Oncol, Perugia, Italy

[4] S Luca Hosp, Dept Oncol, Lucca, Italy

[5] IRCCS, European Inst Oncol, IEO, Div Thorac Surg, Milan, Italy

[6] AUSL Romagna, Dept Oncol & Hematol, Ravenna, Italy

[7] IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, Italy

[8] Polytech Univ Marche Reg, Dept Biol Sci & Publ Hlth, Ancona, Italy

[9] Azienda Osped Riuniti, Pulm Dis Unit, Ancona, Italy

[10] IRCCS Osped Sacro Cuore Don Calabria, Med Oncol, Verona, Italy

[11] Ctr Excellence Aging Univ Fdn, Ctr Predict Mol Med, Chieti, Italy

[12] Univ Turin, San Luigi Hosp, Dept Oncol, Orbassano, Italy

[13] Univ Perugia, S Maria Misericordia Hosp, Div Thorac Surg, Med Sch, Perugia, Italy

[14] Univ Torino, Dept Oncol, Radiat Oncol, Turin, Italy

[15] Fdn IRCCS Casa Sollievo Sofferenza, Div Med Oncol, Foggia, Italy

来源：

TUMORI JOURNAL | 2019年 / 105卷

关键词：

AIOM; non-small cell lung cancer; guidelines; recommendations; RANDOMIZED PHASE-III; PACLITAXEL PLUS CARBOPLATIN; PLATINUM-BASED CHEMOTHERAPY; TYROSINE KINASE INHIBITORS; FACTOR RECEPTOR MUTATIONS; UNCOMMON EGFR MUTATIONS; WILD-TYPE EGFR; OPEN-LABEL; 1ST-LINE TREATMENT; ELDERLY-PATIENTS;

D O I：

10.1177/0300891619857418

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The treatment landscape of metastatic non-small cell lung cancer (NSCLC) has dramatically evolved in recent years, since the recognition of several clinical-biological entities requiring personalized treatment approaches, leading to significant improvements in patients' survival outcomes. In particular, targeted therapies acting against EGFR, ALK, and ROS1, and immunotherapeutic agents modulating the PD-1/PD-L1 axis, represent new milestones in the treatment of advanced disease, supporting a chemotherapy backbone within a multidisciplinary model. The Italian Association of Medical Oncology (AIOM) has developed evidence-based guidelines for the management of lung tumors. Given the epidemiologic relevance, this report is dedicated to the treatment of advanced/metastatic NSCLC. These guidelines serve as a practical tool for oncologists, physicians, and other healthcare professionals to easily embrace the updated key points of NSCLC treatment strategies. Considering the upcoming introduction of potential new standards of care in several disease settings, these guidelines represent a benchmark from which to move forward.

引用

页码：3 / 14

页数：12

共 105 条

[81] Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial [J].

Shaw, Alice T. ;

Felip, Enriqueta ;

Bauer, Todd M. ;

Besse, Benjamin ;

Navarro, Alejandro ;

Postel-Vinay, Sophie ;

Gainor, Justin F. ;

Johnson, Melissa ;

Dietrich, Jorg ;

James, Leonard P. ;

Clancy, Jill S. ;

Chen, Joseph ;

Martini, Jean-Francois ;

Abbattista, Antonello ;

Solomon, Benjamin J. .

LANCET ONCOLOGY, 2017, 18 (12) :1590-1599

[82] Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial [J].

Shaw, Alice T. ;

Kim, Tae Min ;

Crino, Lucio ;

Gridelli, Cesare ;

Kiura, Katsuyuki ;

Liu, Geoffrey ;

Novello, Silvia ;

Bearz, Alessandra ;

Gautschi, Oliver ;

Mok, Tony ;

Nishio, Makoto ;

Scagliotti, Giorgio ;

Spigel, David R. ;

Deudon, Stephanie ;

Zheng, Cheng ;

Pantano, Serafino ;

Urban, Patrick ;

Massacesi, Cristian ;

Viraswami-Appanna, Kalyanee ;

Felip, Enriqueta .

LANCET ONCOLOGY, 2017, 18 (07) :874-886

[83] Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial [J].

Shaw, Alice T. ;

Gandhi, Leena ;

Gadgeel, Shirish ;

Riely, Gregory J. ;

Cetnar, Jeremy ;

West, Howard ;

Camidge, D. Ross ;

Socinski, Mark A. ;

Chiappori, Alberto ;

Mekhail, Tarek ;

Chao, Bo H. ;

Borghaei, Hossein ;

Gold, Kathryn A. ;

Zeaiter, Ali ;

Bordogna, Walter ;

Balas, Bogdana ;

Puig, Oscar ;

Henschel, Volkmar ;

Ou, Sai-Hong Ignatius .

LANCET ONCOLOGY, 2016, 17 (02) :234-242

[84] Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer [J].

Shaw, Alice T. ;

Ou, Sai-Hong I. ;

Bang, Yung-Jue ;

Camidge, D. Ross ;

Solomon, Benjamin J. ;

Salgia, Ravi ;

Riely, Gregory J. ;

Varella-Garcia, Marileila ;

Shapiro, Geoffrey I. ;

Costa, Daniel B. ;

Doebele, Robert C. ;

Long Phi Le ;

Zheng, Zongli ;

Tan, Weiwei ;

Stephenson, Patricia ;

Shreeve, S. Martin ;

Tye, Lesley M. ;

Christensen, James G. ;

Wilner, Keith D. ;

Clark, Jeffrey W. ;

Iafrate, A. John .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (21) :1963-1971

[85] Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer [J].

Shaw, Alice T. ;

Kim, Dong-Wan ;

Nakagawa, Kazuhiko ;

Seto, Takashi ;

Crino, Lucio ;

Ahn, Myung-Ju ;

De Pas, Tommaso ;

Besse, Benjamin ;

Solomon, Benjamin J. ;

Blackhall, Fiona ;

Wu, Yi-Long ;

Thomas, Michael ;

O'Byrne, Kenneth J. ;

Moro-Sibilot, Denis ;

Camidge, D. Ross ;

Mok, Tony ;

Hirsh, Vera ;

Riely, Gregory J. ;

Iyer, Shrividya ;

Tassell, Vanessa ;

Polli, Anna ;

Wilner, Keith D. ;

Jaenne, Pasi A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (25) :2385-2394

[86] Erlotinib in previously treated non-small-cell lung cancer [J].

Shepherd, FA ;

Pereira, JR ;

Ciuleanu, T ;

Tan, EH ;

Hirsh, V ;

Thongprasert, S ;

Campos, D ;

Maoleekoonpiroj, S ;

Smylie, M ;

Martins, R ;

van Kooten, M ;

Dediu, M ;

Findlay, B ;

Tu, DS ;

Johnston, D ;

Bezjak, A ;

Clark, G ;

Santabárbara, P ;

Seymour, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) :123-132

[87] Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy [J].

Shepherd, FA ;

Dancey, J ;

Ramlau, R ;

Mattson, K ;

Gralla, R ;

O'Rourke, M ;

Levitan, N ;

Gressot, L ;

Vincent, M ;

Burkes, R ;

Coughlin, S ;

Kim, Y ;

Berille, J .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (10) :2095-2103

[88] Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975 [J].

Smit, EF ;

van Meerbeeck, JPAM ;

Lianes, P ;

Debruyne, C ;

Legrand, C ;

Schramel, F ;

Smit, H ;

Gaafar, R ;

Biesma, B ;

Manegold, C ;

Neymark, N ;

Giaccone, G .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :3909-3917

[89] Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC [J].

Socinski, M. A. ;

Jotte, R. M. ;

Cappuzzo, F. ;

Orlandi, F. ;

Stroyakovskiy, D. ;

Nogami, N. ;

Rodriguez-Abreu, D. ;

Moro-Sibilot, D. ;

Thomas, C. A. ;

Barlesi, F. ;

Finley, G. ;

Kelsch, C. ;

Lee, A. ;

Coleman, S. ;

Deng, Y. ;

Shen, Y. ;

Kowanetz, M. ;

Lopez-Chavez, A. ;

Sandler, A. ;

Reck, M. ;

Ahualli, A. ;

Jarchum, G. ;

Kaen, D. L. ;

Kahl, S. ;

Kotliar, M. ;

Kowalyszyn, R. D. ;

Lerzo, G. ;

Magri, I ;

Martin, C. ;

Pastor, A. ;

Picon, P. ;

Streich, G. ;

Varela, M. ;

Blinman, P. ;

Boyer, M. ;

Crombie, C. ;

Gauden, S. ;

Gill, S. ;

Hughes, B. ;

John, T. ;

Joshi, A. ;

Kosmider, S. ;

Lewis, C. ;

Millward, M. ;

Nordman, I ;

Nott, L. ;

O'Byrne, K. ;

Parnis, F. ;

Potasz, N. ;

Richardson, G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (24) :2288-2301

[90] Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study [J].

Solomon, Benjamin J. ;

Besse, Benjamin ;

Bauer, Todd M. ;

Felip, Enriqueta ;

Soo, Ross A. ;

Camidge, D. Ross ;

Chiari, Rita ;

Bearz, Alessandra ;

Lin, Chia-Chi ;

Gadgeel, Shirish M. ;

Riely, Gregory J. ;

Tan, Eng Huat ;

Seto, Takashi ;

James, Leonard P. ;

Clancy, Jill S. ;

Abbattista, Antonello ;

Martini, Jean-Francois ;

Chen, Joseph ;

Peltz, Gerson ;

Thurm, Holger ;

Ou, Sai-Hong Ignatius ;

Shaw, Alice T. .

LANCET ONCOLOGY, 2018, 19 (12) :1654-1667

← 2 3 4 5 6 7 8 9 10 11 →